Lifastuzumab
This product is a humanized IgG1 monoclonal antibody that targets NaPi2b (sodium-dependent phosphate transport protein 2b, also called SLC34A2). NaPi2b is overexpressed in several cancers, including ovarian, lung, and other epithelial tumors, making it an especially promising therapeutic target. Lifastuzumab has been developed both as a naked antibody and as part of antibody–drug conjugates (ADCs) such as lifastuzumab vedotin, specifically designed to deliver cytotoxic agents to NaPi2b-positive tumor cells.
Key Features and Benefits
-
Target Specificity: Recognizes NaPi2b, a transporter highly expressed in ovarian and lung cancers.
-
Therapeutic Versatility: Studied as both a naked antibody and ADC format.
-
ADC Compatibility: Conjugates with cytotoxic payloads for targeted delivery.
-
Humanized IgG1: Reduces immunogenicity and extends circulation half-life.
-
Clinical Relevance: Investigated in multiple oncology indications.
Applications
-
Oncology Research: Explores NaPi2b as a therapeutic target in ovarian and lung cancer.
-
ADC Development: Serves as the targeting component in lifastuzumab vedotin.
-
Diagnostics: Enables detection of NaPi2b expression in tumors.
-
Drug Discovery: Provides a platform for developing NaPi2b-directed therapies.
Storage and Handling
-
Storage: Store at 2–8 °C in original packaging; protect from light.
-
Handling: Do not freeze; use aseptic conditions for clinical formulations.
This product is an important anti-NaPi2b monoclonal antibody, specifically serving as the foundation for novel antibody-based therapeutics, including lifastuzumab vedotin.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
